Key result
Fabomotizole plus ALM-802 minimizes atrial arrhythmias in alcoholic cardiomyopathy rats by eliminating early activation areas.
Why the study?
Alcoholic cardiomyopathy is a leading cause of mortality associated with an increased risk of malignant cardiovascular disease, driving the search for new drugs with antiarrhythmic activity.
Does combination therapy with fabomotizole and ALM-802 improve atrial depolarization in a rat model of alcoholic cardiomyopathy?
Does combination therapy with fabomotizole and ALM-802 improve atrial depolarization in a rat model of alcoholic cardiomyopathy?
In a rat model of alcoholic cardiomyopathy, combination therapy with fabomotizole and ALM-802 improved atrial depolarization and reduced the risk of atrial arrhythmias.
Hypothesis-generating for atrial arrhythmia prevention in alcoholic cardiomyopathy; leaves open human translation pending clinical trials.
Relevance. Alcoholic cardiomyopathy (ACMP) is the leading cause of mortality in chronic disease, which is largely associated with an increased risk of developing malignant diseases of the cardiovascular disease. Search for new drugs, including those exhibiting pronounced antiarrhythmic activity, supposed relevance. Objective. To study the effect of combination therapy with fabomotizole and ALM-802 on atrial depolarization in a translational model of alcoholic cardiomyopathy in rats. Methods. The sequence of depolarization of the atrial epicardium was studied in rats in a translational model of alcoholic cardiomyopathy, which received a combination of fabomotizole and compound ALM-802 daily for 28 days after the end of 24 weeks of alcoholization, or pyrogen-free water intraperitoneally. Results. As a result of the 28-day combined action of fabomotizole and the compound ALM-802 in animals with alcoholic cardiomyopathy, additional areas of early activation in the area of lacunae of the pulmonary veins that form during the 24-week period of alcoholization disappear, the risk of atrial arrhythmias is minimized, and sequential propagation.
No takes yet. Share an insight, caveat, or question.
Смирнова et al. (2023) studied Alcoholic cardiomyopathy. Combination of fabomotizole and compound ALM-802 vs. Pyrogen-free water intraperitoneally was evaluated on Sequence of depolarization of the atrial epicardium. Combination therapy with fabomotizole and ALM-802 in rats with alcoholic cardiomyopathy eliminated early activation areas and minimized the risk of atrial arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: